People in the News: Michael Perry Dec 22, 2011 Premium Save for later Arrowhead Research has named Michael Perry to its board of directors. Perry is currently a venture partner at investment fund Bay City Capital. He is also president and CMO of Poniard Pharmaceuticals. Filed under Gene Silencing/Gene Editing RNAi Arrowhead Breaking News CRISPR Researchers Engineer Guide RNAs to Enhance Cas13 Gene Knockdown TwinStrand Biosciences Sues Guardant Health for Alleged Patent Infringement Pacific Biosciences Acquires Sample Preparation Firm Circulomics Singular Genomics Systems Reports No Revenues, Increased Net Loss for Q2 Burning Rock Biotech, Impact Therapeutics Partner on CDx for PARP Inhibitor Senaparib Gene Editing Analysis Firm SeQure Dx Closes $17.5M Series A Funding Round The Scan Push Toward Approval The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines. Deer Exposure About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News. Millions But Not Enough NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed. PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.